Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year operating income growth rate
Percentile
P87
Within normal range
vs 2Y Ago
2.9x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 24.14% |
| Q2 2025 | 54.90% |
| Q1 2025 | -121.69% |
| Q4 2024 | 40.44% |
| Q3 2024 | -1.47% |
| Q2 2024 | -29.39% |
| Q1 2024 | 7.21% |
| Q4 2023 | 27.93% |
| Q3 2023 | 8.25% |
| Q2 2023 | -35.03% |
| Q1 2023 | -2.59% |
| Q4 2022 | -15.23% |
| Q3 2022 | -24.83% |
| Q2 2022 | -52.01% |
| Q1 2022 | 35.83% |
| Q4 2021 | -24.41% |
| Q3 2021 | -27.47% |
| Q2 2021 | 5.53% |
| Q1 2021 | 16.52% |
| Q4 2020 | -14.64% |
| Q3 2020 | -20.40% |
| Q2 2020 | 17.97% |
| Q1 2020 | -22.65% |
| Q4 2019 | 30.34% |
| Q3 2019 | -30.79% |
| Q2 2019 | 10.76% |
| Q1 2019 | 10.45% |
| Q4 2018 | -2.69% |
| Q3 2018 | -26.13% |
| Q2 2018 | 22.68% |
| Q1 2018 | -22.03% |
| Q4 2017 | 22.23% |
| Q3 2017 | 7.05% |
| Q2 2017 | 7.72% |
| Q1 2017 | -14.34% |
| Q4 2016 | 3.86% |
| Q3 2016 | -2.65% |
| Q2 2016 | -15.26% |
| Q1 2016 | -21.99% |
| Q4 2015 | -6.03% |